Fig. 4
From: Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Summary of CRISPR-Cas9 editing strategies to generate optimally potent and widely available CAR T-cell products. a CRISPR-Cas9 editing can be used to develop allogeneic CAR T-cell therapies, which will ameliorate many of the current issues associated with autologous CAR T-cell products. b Removal of the endogenous TCR by targeting TRAC via CAR transgene knock-in addresses histocompatibility barriers associated with third party cell products derived from unrelated donors. c Multiplex CRISPR-Cas9 editing can be used to enhance the antitumor efficacy and improve the safety of autologous or allogeneic CAR T-cell products. CRISPR-Cas9-mediated precision editing of clonal master iPSC lines has the potential to generate a renewable cell source that can be repeatedly used to mass produce homogeneous, optimally potent, ‘best-in-class’ universal CAR T-cell products in a cost-effective manner. Created with BioRender.com